BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3288299)

  • 1. Semantics and the chemotherapy of Hodgkin's disease--resistance is not relapse: alternative chemotherapy lacks effectiveness for disease not totally responsive to initial MOPP treatment.
    Coleman M; Friedlander RJ
    Cancer Invest; 1988; 6(2):237-9. PubMed ID: 3288299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
    Tannir N; Hagemeister F; Velasquez W; Cabanillas F
    J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
    Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
    Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.
    Bonadonna G; Valagussa P; Santoro A
    Ann Intern Med; 1986 Jun; 104(6):739-46. PubMed ID: 2422994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology.
    Oberlin O; Leverger G; Pacquement H; Raquin MA; Chompret A; Habrand JL; Terrier-Lacombe MJ; Bey P; Bertrand Y; Rubie H
    J Clin Oncol; 1992 Oct; 10(10):1602-8. PubMed ID: 1383434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin combinations as salvage therapy in advanced MOPP-resistant Hodgkin's disease.
    Olver IN; Wolf MM; Bishop JF; Ding JC; Cooper IA; Matthews J
    Aust N Z J Med; 1983 Aug; 13(4):369-73. PubMed ID: 6197053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
    Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
    Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Four cases of Hodgkin's disease treated with MOPP/ABV hybrid regimen using nitrogen mustard-N-oxide hydrochloride].
    Kozai Y; Ohyama T; Kodo H; Tomori G
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2407-9. PubMed ID: 1281397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [MOPP therapy of Hodgkin's disease previously treated with MOPP].
    Frau A; Montalar J
    Med Clin (Barc); 1985 May; 84(19):801. PubMed ID: 3839875
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
    Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
    J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.
    Diehl LF; Perry DJ; Terebelo H; Baldwin PE; Hurwitz M; Kimball DB; Dorn RV
    Cancer Treat Rep; 1983 Sep; 67(9):827-9. PubMed ID: 6883360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
    Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.